Héctor G. Palmer’s Stem Cells & Cancer Group studies the mechanisms that enable tumors to persist by evading effective treatments and progressing to advanced stages of disease.
His team uses multi-omics approaches to reveal unexpected alterations related to tumor and single cell phenotypes. Combining gene editing (CRISPR/Cas) with classical signaling biochemistry in cancer cell lines as well as genetically modified mice, patient-derived organoids (PDO) and xenografts (PDX), is group investigates the functional relevance of these newly identified alterations in patients’ response to therapies.